VLA15, a new global Lyme disease vaccine undergoes clinical trials

0577347 - BC 2024 RIV NL eng O - Ostatní výsledky
Hajdušek, Ondřej - Perner, Jan
VLA15, a new global Lyme disease vaccine undergoes clinical trials.
2023. Lancet Infectious Diseases. Elsevier. Roč. 23, č. 10 (2023), s. 1105-1106. ISSN 1473-3099. E-ISSN 1474-4457
Institucionální podpora: RVO:60077344
Klíčová slova: Lyme disease * vaccine * VLA15
Obor OECD: Infectious Diseases
https://www.sciencedirect.com/science/article/pii/S1473309923003122?via%3Dihub

Lyme disease (Lyme borreliosis) is a tick-borne bacterial infection that occurs in the temperate climates of North America and Eurasia. Treatment with antibiotics is effective only in the early stages of infection. Although the first human Lyme disease vaccine (LYMErix by SmithKline Beecham, Pittsburgh, PA, USA) was marketed and distributed in the USA from 1998 until 2002, it was discontinued and no vaccine is currently available.1, 2, 3 In The Lancet Infectious Diseases, Nicole Bézay and colleagues report the results of a randomised, phase 1, clinical trial in healthy adults immunised with Valneva's novel, multivalent outer surface protein A (OspA) subunit vaccine called VLA15.4
Trvalý link: https://hdl.handle.net/11104/0346788